Cargando…

Dystrophin involvement in peripheral circadian SRF signalling

Absence of dystrophin, an essential sarcolemmal protein required for muscle contraction, leads to the devastating muscle-wasting disease Duchenne muscular dystrophy. Dystrophin has an actin-binding domain, which binds and stabilises filamentous-(F)-actin, an integral component of the RhoA-actin-seru...

Descripción completa

Detalles Bibliográficos
Autores principales:	Betts, Corinne A, Jagannath, Aarti, van Westering, Tirsa LE, Bowerman, Melissa, Banerjee, Subhashis, Meng, Jinhong, Falzarano, Maria Sofia, Cravo, Lara, McClorey, Graham, Meijboom, Katharina E, Bhomra, Amarjit, Lim, Wooi Fang, Rinaldi, Carlo, Counsell, John R, Chwalenia, Katarzyna, O’Donovan, Elizabeth, Saleh, Amer F, Gait, Michael J, Morgan, Jennifer E, Ferlini, Alessandra, Foster, Russell G, Wood, Matthew JA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Life Science Alliance LLC 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363758/ https://www.ncbi.nlm.nih.gov/pubmed/34389686 http://dx.doi.org/10.26508/lsa.202101014

Ejemplares similares

Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology
por: van Westering, Tirsa L.E., et al.
Publicado: (2019)

Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment
por: Betts, Corinne A, et al.
Publicado: (2019)

Light modulation ameliorates expression of circadian genes and disease progression in spinal muscular atrophy mice
por: Walter, Lisa M, et al.
Publicado: (2018)

Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics
por: McClorey, Graham, et al.
Publicado: (2018)

Exon skipping induces uniform dystrophin rescue with dose-dependent restoration of serum miRNA biomarkers and muscle biophysical properties
por: Chwalenia, Katarzyna, et al.
Publicado: (2022)

Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy
por: Malerba, Alberto, et al.
Publicado: (2012)

Effects of Mini-Dystrophin on Dystrophin-Deficient, Human Skeletal Muscle-Derived Cells
por: Meng, Jinhong, et al.
Publicado: (2020)

Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration
por: Roberts, Thomas C., et al.
Publicado: (2015)

Splice-Switching Therapy for Spinal Muscular Atrophy
por: Meijboom, Katharina E., et al.
Publicado: (2017)

Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment
por: Gait, Michael J., et al.
Publicado: (2019)

Current Understanding of Molecular Pathology and Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy
por: van Westering, Tirsa L. E., et al.
Publicado: (2015)

Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy
por: Shabanpoor, Fazel, et al.
Publicado: (2015)

Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy
por: Blain, Alison M., et al.
Publicado: (2018)

Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin/utrophin double-knockout mouse model of DMD
por: Hanson, Britt, et al.
Publicado: (2022)

Expression Analysis in Multiple Muscle Groups and Serum Reveals Complexity in the MicroRNA Transcriptome of the mdx Mouse with Implications for Therapy
por: Roberts, Thomas C, et al.
Publicado: (2012)

Modulating the Expression of Disease Genes with RNA-Based Therapy
por: Wood, Matthew, et al.
Publicado: (2007)

mRNA in situ hybridization exhibits unbalanced nuclear/cytoplasmic dystrophin transcript repartition in Duchenne myogenic cells and skeletal muscle biopsies
por: Falzarano, Maria Sofia, et al.
Publicado: (2023)

Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics
por: Coenen-Stass, Anna M. L., et al.
Publicado: (2015)

Corrigendum: Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics
por: Coenen-Stass, Anna M. L., et al.
Publicado: (2016)

Optimized lentiviral vector to restore full-length dystrophin via a cell-mediated approach in a mouse model of Duchenne muscular dystrophy
por: Meng, Jinhong, et al.
Publicado: (2022)

Lentiviral vectors can be used for full-length dystrophin gene therapy
por: Counsell, John R., et al.
Publicado: (2017)

Lentiviral vectors can be used for full-length dystrophin gene therapy
por: Counsell, John R., et al.
Publicado: (2017)

Erratum: Lentiviral vectors can be used for full-length dystrophin gene therapy
por: Counsell, John R., et al.
Publicado: (2017)

The DMD Locus Harbours Multiple Long Non-Coding RNAs Which Orchestrate and Control Transcription of Muscle Dystrophin mRNA Isoforms
por: Bovolenta, Matteo, et al.
Publicado: (2012)

Biodistribution and Molecular Studies on Orally Administered Nanoparticle-AON Complexes Encapsulated with Alginate Aiming at Inducing Dystrophin Rescue in mdx Mice
por: Falzarano, Maria Sofia, et al.
Publicado: (2013)

Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy
por: Betts, Corinne A., et al.
Publicado: (2015)

Autologous skeletal muscle derived cells expressing a novel functional dystrophin provide a potential therapy for Duchenne Muscular Dystrophy
por: Meng, Jinhong, et al.
Publicado: (2016)

SRF for Muon Colliders
por: Padamsee, H
Publicado: (2000)

Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice
por: Betts, Corinne A., et al.
Publicado: (2015)

NLK is required for Ras/ERK/SRF/ELK signaling to tune skeletal muscle development by phosphorylating SRF and antagonizing the SRF/MKL pathway
por: Li, Shang-Ze, et al.
Publicado: (2022)

Urinary Stem Cells as Tools to Study Genetic Disease: Overview of the Literature
por: Falzarano, Maria Sofia, et al.
Publicado: (2019)

Developments on SRF coatings at CERN
por: Sublet, Alban, et al.
Publicado: (2015)

SRF for Future Circular Colliders
por: Calaga, Rama, et al.
Publicado: (2015)

Daresbury: SRF successful start
Publicado: (1972)

SRF Cavity Fabrication and Materials
por: Singer, W
Publicado: (2015)

Annual Report of the SRF Collaboration
por: Proch, D, et al.
Publicado: (2005)

Annual Report of the SRF Collaboration
por: Proch, D, et al.
Publicado: (2006)

Annual Report of the SRF Collaboration
por: Proch, D, et al.
Publicado: (2007)

Annual Report of the SRF Collaboration
por: Proch, D, et al.
Publicado: (2008)

Persistent Dystrophin Protein Restoration 90 Days after a Course of Intraperitoneally Administered Naked 2′OMePS AON and ZM2 NP-AON Complexes in mdx Mice
por: Bassi, Elena, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_pqb3h1kerr12r9ofnav438v7aa